Related Experiment Videos
The Medtronic-Hall cardiac valve: 7 1/2 years' clinical experience
Insights
The Medtronic-Hall valve prosthesis shows good long-term survival and functional outcomes in patients undergoing aortic or mitral valve replacement. Complications were minimal, with low rates of thromboembolism and no structural failures.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Clinical Outcomes Research
Background:
- Mechanical heart valve prostheses are crucial for treating valvular heart disease.
- The Medtronic-Hall valve is a bileaflet mechanical prosthesis with a long history of clinical use.
- Assessing long-term outcomes and complications is essential for patient management.
Purpose of the Study:
- To evaluate the long-term clinical performance of the Medtronic-Hall valve prosthesis.
- To assess survival rates, functional status, and complication incidence after aortic valve replacement (AVR), mitral valve replacement (MVR), and double valve replacement (DVR).
Main Methods:
- Retrospective review of 379 patients who received Medtronic-Hall valve prostheses.
- Analysis of clinical data over 90 months (1,225 patient-years).
- Inclusion of patients undergoing AVR, MVR, and DVR, with and without concomitant procedures.
Main Results:
- Actuarial survival at 7.5 years was 74.1% overall (AVR: 69.0%, MVR: 81.0%, DVR: 67.0%).
- Low rates of thromboembolic events (2.1/100 patient-years) and no structural valve failures were observed.
- 92% of late survivors improved to New York Heart Association Functional Class I or II.
Conclusions:
- The Medtronic-Hall valve prosthesis demonstrates favorable long-term durability and clinical outcomes.
- The prosthesis is associated with acceptable thromboembolic complication rates when patients are managed with anticoagulation.
- High rates of functional improvement in survivors indicate good quality of life post-implantation.
Abstract:
Clinical information on the Medtronic-Hall valve prosthesis was obtained by reviewing the records of 379 patients, 164 of whom had aortic valve replacement (AVR), 163 of whom had mitral valve replacement (MVR), and 52 of whom had double valve replacement over 90 months (1,225 patient-years) (mean follow-up, 42.01 +/- 1.3 months [+/- standard error]). Mean age was 53.8 +/- 12 years. One hundred ninety-three patients (50.9%) had some type of concomitant operation, such as tricuspid annuloplasty, coronary artery bypass grafting, or resection of ascending aortic aneurysm. Ninety-one percent were in New York Heart Association (NYHA) Functional Class III or IV preoperatively. Early mortality and late mortality were 7.7% (29 patients) and 13.5% (51 patients), respectively. The actuarial survival at 7 1/2 years was 74.1 +/- 2.7% for the total group and 69.0 +/- 4.5% for those having AVR, 81.0 +/- 3.2% for those having MVR, and 67.0 +/- 8.9% for those having double valve replacement. All patients but 2 were maintained on a regimen of chronic anticoagulation with warfarin sodium. Twenty-six thromboembolic episodes occurred (2.1/100 patient-years): 13 after MVR (2.3/100 patient-years), 11 after AVR (2.1/100 patient-years), and 2 after double valve replacement (1.4/100 patient-years). Four thromboembolic episodes were fatal; no valve thrombosis occurred. There were no structural failures. Of the 350 late survivors, 92% were in NYHA Functional Classes I and II. Total valve-related complications have been minimal.(ABSTRACT TRUNCATED AT 250 WORDS)